Savara Inc
NASDAQ:SVRA

Watchlist Manager
Savara Inc Logo
Savara Inc
NASDAQ:SVRA
Watchlist
Price: 3.23 USD Market Closed
Market Cap: 554.3m USD
Have any thoughts about
Savara Inc?
Write Note

Savara Inc
Cash Interest Paid

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Savara Inc
Cash Interest Paid Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash Interest Paid CAGR 3Y CAGR 5Y CAGR 10Y
Savara Inc
NASDAQ:SVRA
Cash Interest Paid
$2.2m
CAGR 3-Years
3%
CAGR 5-Years
2%
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Cash Interest Paid
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Gilead Sciences Inc
NASDAQ:GILD
Cash Interest Paid
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Amgen Inc
NASDAQ:AMGN
Cash Interest Paid
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Cash Interest Paid
$38.3m
CAGR 3-Years
-12%
CAGR 5-Years
-8%
CAGR 10-Years
20%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Cash Interest Paid
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Savara Inc
Glance View

Market Cap
551.8m USD
Industry
Biotechnology

Savara, Inc. is a clinical-stage pharmaceutical company, which engages in the development and commercialization of novel therapies for the treatment of serious or life-threatening rare respiratory diseases. The company is headquartered in Austin, Texas and currently employs 22 full-time employees. The company went IPO on 2001-06-25. The firm is focused on rare respiratory diseases. The Company’s lead program, molgramostim nebulizer solution (molgramostim), is an inhaled granulocyte-macrophage colony-stimulating factor in Phase III development for autoimmune pulmonary alveolar proteinosis (aPAP). Molgramostim an inhaled formulation of recombinant human GM-CSF, is being developed for the treatment of aPAP. Pulmonary alveolar proteinosis (PAP) is a rare lung disease characterized by the build-up of surfactant in the alveoli or air sacs of the lungs.

SVRA Intrinsic Value
2.14 USD
Overvaluation 34%
Intrinsic Value
Price

See Also

What is Savara Inc's Cash Interest Paid?
Cash Interest Paid
2.2m USD

Based on the financial report for Sep 30, 2024, Savara Inc's Cash Interest Paid amounts to 2.2m USD.

What is Savara Inc's Cash Interest Paid growth rate?
Cash Interest Paid CAGR 5Y
2%

Over the last year, the Cash Interest Paid growth was 12%. The average annual Cash Interest Paid growth rates for Savara Inc have been 3% over the past three years , 2% over the past five years .

Back to Top